DK1478659T3 - Biologisk aktive peptider - Google Patents

Biologisk aktive peptider

Info

Publication number
DK1478659T3
DK1478659T3 DK02749008T DK02749008T DK1478659T3 DK 1478659 T3 DK1478659 T3 DK 1478659T3 DK 02749008 T DK02749008 T DK 02749008T DK 02749008 T DK02749008 T DK 02749008T DK 1478659 T3 DK1478659 T3 DK 1478659T3
Authority
DK
Denmark
Prior art keywords
biologically active
active peptides
disclosed
nucleic acids
pharmaceutical formulation
Prior art date
Application number
DK02749008T
Other languages
Danish (da)
English (en)
Inventor
Wai Ming Wong
Kong Lam
Original Assignee
Cms Peptides Patent Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Peptides Patent Holding Co filed Critical Cms Peptides Patent Holding Co
Application granted granted Critical
Publication of DK1478659T3 publication Critical patent/DK1478659T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK02749008T 2001-07-13 2002-07-11 Biologisk aktive peptider DK1478659T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90449201A 2001-07-13 2001-07-13
PCT/GB2002/003203 WO2003006492A2 (en) 2001-07-13 2002-07-11 Biologically active peptides

Publications (1)

Publication Number Publication Date
DK1478659T3 true DK1478659T3 (da) 2009-01-05

Family

ID=25419251

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02749008T DK1478659T3 (da) 2001-07-13 2002-07-11 Biologisk aktive peptider
DK07000950.1T DK1790655T3 (da) 2001-07-13 2002-07-11 Biologisk aktive peptider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07000950.1T DK1790655T3 (da) 2001-07-13 2002-07-11 Biologisk aktive peptider

Country Status (24)

Country Link
EP (3) EP1790655B1 (de)
JP (3) JP4213581B2 (de)
KR (2) KR100889993B1 (de)
AT (2) ATE466871T1 (de)
AU (1) AU2002319423B2 (de)
BR (1) BR0210252A (de)
CA (2) CA2452417C (de)
DE (2) DE60229883D1 (de)
DK (2) DK1478659T3 (de)
ES (2) ES2345842T3 (de)
HK (2) HK1066552A1 (de)
IL (2) IL159827A0 (de)
MX (1) MXPA03011190A (de)
MY (1) MY138219A (de)
NO (2) NO332061B1 (de)
NZ (3) NZ553507A (de)
PL (2) PL208666B1 (de)
PT (2) PT1790655E (de)
RU (2) RU2425053C2 (de)
SA (1) SA04240478B1 (de)
SG (2) SG185137A1 (de)
UA (1) UA83989C2 (de)
WO (1) WO2003006492A2 (de)
ZA (2) ZA200401108B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1216069C (zh) 2001-07-13 2005-08-24 一泰医药研究（深圳）有限公司 序列号25的生物活性肽
WO2004055042A1 (en) * 2002-12-18 2004-07-01 Pepharm R & D Limited Biologically active peptide conjugates
TWI322815B (en) * 2003-06-26 2010-04-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide comprising tyrosyl-seryl-valine (ysv)
TWI353252B (en) * 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
CN1799623B (zh) * 2005-01-05 2011-01-26 康哲医药研究(深圳)有限公司 生物活性肽在制备用于防治关节炎的药物中的用途
US8586525B2 (en) 2005-07-26 2013-11-19 Cms Peptides Patent Holding Company Limited Biologically active peptides and their new uses
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242821A (en) 1989-07-10 1993-09-07 Valio, Finnish Co-Operative Dairies' Association Lactococcus promoter and signal sequences for expression in bacteria
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
AU7142391A (en) * 1989-12-22 1991-07-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides as modulators of functional responses of intact cells
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
WO1994029450A2 (en) 1993-06-15 1994-12-22 E.I. Du Pont De Nemours And Company Novel, recombinantly produced spider silk analogs
JP3286420B2 (ja) 1993-09-28 2002-05-27 株式会社ユニシアジェックス 内燃機関の吸排気弁駆動制御装置
JPH10503643A (ja) 1994-06-17 1998-04-07 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 微生物中に遺伝物質を導入する方法およびその方法によってえられる形質転換体
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
DE69633133T2 (de) 1995-10-24 2005-07-28 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute TFPI-verwandte Peptide die das Wachstums von glatten Muskelzellen inhibieren
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
GB9710762D0 (en) * 1997-05-23 1997-07-23 Cancer Res Inst Royal Binding complexes
EP1015612B1 (de) 1997-05-27 2005-01-26 Hanil Synthetic Fiber Co., Ltd. Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
US6653076B1 (en) * 1998-08-31 2003-11-25 The Regents Of The University Of Washington Stable isotope metabolic labeling for analysis of biopolymers
US6413530B1 (en) * 1999-04-21 2002-07-02 University Of Florida Research Foundation, Inc. Pesticidal peptides
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001032853A1 (en) * 1999-10-29 2001-05-10 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same

Also Published As

Publication number Publication date
IL184227A (en) 2010-06-16
KR20040019058A (ko) 2004-03-04
SA04240478B1 (ar) 2007-07-31
JP4213581B2 (ja) 2009-01-21
NO20073914L (no) 2004-03-10
UA83989C2 (ru) 2008-09-10
DE60229883D1 (de) 2008-12-24
ZA200401108B (en) 2006-05-31
MXPA03011190A (es) 2004-10-28
NO20040134L (no) 2004-03-10
DK1790655T3 (da) 2010-08-23
EP1790655B1 (de) 2010-05-05
CA2452417A1 (en) 2003-01-23
IL184227A0 (en) 2007-10-31
RU2305107C2 (ru) 2007-08-27
EP1947109A3 (de) 2008-10-01
EP1478659B1 (de) 2008-11-12
ZA200509838B (en) 2007-11-28
RU2425053C2 (ru) 2011-07-27
RU2004104335A (ru) 2005-03-27
IL159827A0 (en) 2004-06-20
ES2345842T3 (es) 2010-10-04
HK1098767A1 (en) 2007-07-27
PT1478659E (pt) 2009-01-02
EP1790655A2 (de) 2007-05-30
BR0210252A (pt) 2004-09-14
AU2002319423B2 (en) 2008-02-14
KR20070070258A (ko) 2007-07-03
JP2008263993A (ja) 2008-11-06
RU2007108896A (ru) 2008-09-20
CA2707767A1 (en) 2003-01-23
CA2452417C (en) 2013-08-20
NZ553507A (en) 2008-07-31
JP2004533846A (ja) 2004-11-11
PL208666B1 (pl) 2011-05-31
ES2316586T3 (es) 2009-04-16
JP2007312785A (ja) 2007-12-06
ATE466871T1 (de) 2010-05-15
PT1790655E (pt) 2010-07-09
EP1790655A3 (de) 2007-10-10
MY138219A (en) 2009-05-29
NO332061B1 (no) 2012-06-11
ATE414099T1 (de) 2008-11-15
HK1066552A1 (en) 2005-03-24
DE60236330D1 (de) 2010-06-17
EP1947109A2 (de) 2008-07-23
WO2003006492A2 (en) 2003-01-23
PL368059A1 (en) 2005-03-21
KR100889993B1 (ko) 2009-03-25
SG185137A1 (en) 2012-11-29
NZ529879A (en) 2007-12-21
PL211884B1 (pl) 2012-07-31
SG142165A1 (en) 2008-05-28
KR100889992B1 (ko) 2009-03-25
JP4316651B2 (ja) 2009-08-19
EP1478659A2 (de) 2004-11-24
CA2707767C (en) 2013-09-03
WO2003006492A3 (en) 2003-12-31
NZ544079A (en) 2007-10-26

Similar Documents

Publication Publication Date Title
NO20073914L (no) Biologisk aktive peptider
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
BR0312889A (pt) Polipeptìdeo t20 peguilado
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
TW200611913A (en) Biologically active peptides (Ⅲ)
DE60039708D1 (de) Menschliches chordin und polynukleotiden die dafür kodieren
ATE526308T1 (de) 13-substituierte methacyclinverbindungen
FR2820425B1 (fr) Melange de peptides issus d'une proteine nef et leurs applications
CA2530618A1 (en) Novel calcium channel
IT1298437B1 (it) Procedimento per la produzione di proteine/peptidi tossici
BR0107799A (pt) Proteìna de interação de wt1 wtip